目的 制备美洛昔康纳米晶舌下速溶膜(MLX-NS-FDSFs),优化其处方,并考察其体外溶出。方法 采用pH依赖的溶解沉淀联合高速剪切法制备美洛昔康纳米晶(MLX-NS),进一步制成舌下速溶膜。以羟丙甲基纤维素E30(HPMC-E30)质量浓度、聚乙二醇400(PEG-400)质量浓度和MLX-NS加入体积为考察因素,以膜复溶后纳米粒的粒径、崩解时间和拉伸长度为指标,采用Box-Behnken设计试验优化MLX-NS-FDSFs处方。考察以最优处方制备的MLX-NS-FDSFs的形态、含量均匀度和体外溶出度。结果 以最优处方35 mg·mL-1 HPMC-E30、40 mg·mL-1 PEG-400、10 mL MLX-NS制得的MLX-NS-FDSFs复溶后的纳米粒粒径为(186.4±6.3)nm,崩解时间为(26.08±1.76)s、拉伸长度为(1.51±0.13)mm,理论预测值与实测值偏差较小,模型具有良好的预测性。形态分析结果显示,MLX纳米粒均匀的分散在膜内,含量均匀度符合规定,MLX在5 min内释放度达到(91.75±8.05)%。结论 采用Box-Behnken效应面法优化MLX-NS-FDSFs处方是可行、有效的,MLX-NS-FDSFs可显著提高MLX的累积溶出度。
Abstract
OBJECTIVE To prepare and optimize meloxicam nanosuspensions fast dissolving sublingual films (MLX-NS-FDSFs) and to evaluate its in vitro dissolution characteristics. METHODS Meloxicam nanosuspensions (MLX-NS) were prepared by pH-dependent dissolving-precipitating/high speed shearing method and then transformed into fast dissolving sublingual films (FDSFs). The formulations of MLX-NS-FDSFs were optimized by employing Box-Behnken design-response surface methodology with the amount of HPMC-E30, PEG-400 and MLX-NS as investigation factors, and particle size of reconstituted nanoparticles from MLX-NS-FDSFs, disintegration time and stretch length as indexes. The morphology, content uniformity and in vitro dissolution of the optimal formulation were also evaluated. RESULTS The MLX-NS-FDSFs prepared by optimized formulation (35 mg·mL-1 HPMC-E30, 40 mg·mL-1 PEG-400, 10 mL MLX-NS) could fast disintegrate in (26.08±1.76) s, the tensile length was (1.51±0.13) mm, and the particle size of reconstituted nanoparticles from MLX-NS-FDSFs was (186.4±6.3) nm. There was a little deviation between the theoretically predicted value and the measured value. It showed that this model had a good prediction. Morphological analysis showed that well-dispersed MLX nanoparticles embedded in MLX-NS-FDSFs. The conformity of drug content was up to standard. MLX could be released in vitro as much as (91.75±8.05)% within five minutes. CONCLUSION Using Box-Behnken design and response surface method to optimize MLX-NS-FDSFs is effective and feasible. MLX-NS-FDSFs can significantly increase the cumulative dissolution of MLX.
关键词
美洛昔康 /
纳米晶 /
舌下速溶膜 /
Box-Behnken效应面法 /
体外溶出度
{{custom_keyword}} /
Key words
meloxicam /
nanosuspension /
fast dissolving sublingual film /
Box-Behnken design-response surface methodology /
in vitro dissolution
{{custom_keyword}} /
中图分类号：
R944
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] AHMED M, KHANNA D, FRUST D E. Meloxicam in rheumatoid arthritis [J]. Expert Opin Drug Metab Toxicol, 2005, 1(4):739-751.
[2] MEUWESEN W P, DU PLESSIS J M, BURGER J R, et al. Prescribing patterns of non-steroidal anti-inflammatory drugs in chronic kidney disease patients in the South African private sector [J]. Int J Clin Pharm, 2016, 38(4): 863-869.
[3] LI X, ZHOU Y, YAN S, et al. Analysis of the use of analgesics in 100 postoperative patients [J]. Chin J Pharmacoepidemiol(药物利用与药物经济), 2010, 19(1):36-38.
[4] OLSON M E, BRENDA R, LES B, et al. Efficacy of oral meloxicam suspension for prevention of pain and inflammation following band and surgical castration in calves [J]. BMC Vet Res, 2016, 12(1): 102.
[5] ZHANG Q, GUAN S. Efficacy and safety evaluation of meloxicam for orthopedic patients with postoperative analgesia [J]. Prac Pharm Clin Remed(实用药物与临床), 2014, 17(4):448-450.
[6] AOKI T, YAMAGUCHI H, NAITO H, et al. Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery [J]. Int J Ora Maxillofac Surg, 2006, 35:613-617.
[7] SHEN C, WANG Y, XU H, et al. Optimization of novel herpetrione nanosuspension orodispersible film by Box-Behnken design-response surface method [J]. Chin Tradit Herb Drugs(中草药), 2014, 45(1): 37-41.
[8] SHEN B D, SHEN C Y, YUAN X D, et al. Development and characterization of an orodispersible film containing drug nanoparticles [J]. Eur J Pharm Biopharm, 2013, 85(3 Pt B):1348-1356.
[9] KOLAND M, SANDEEP V P, CHARYULU N R. Fast dissolving sublingual films of ondansetron hydrochloride: effect of additives on in vitro drug release and mucosalpermeation [J]. J Young Pharm, 2010, 2(3):216-222.
[10] SAYAD S, IBRAHIM H K, MOHAMED M I, et al. Fast-dissolving sublingual films of terbutaline sulfate: formulation and in vitro/in vivo evaluation [J]. Mol Pharm, 2013, 10(8): 2942-2947.
[11] AYAT A, GIHAN F. Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate [J]. Drug Des Develop Ther, 2016, 10:2421-2433.
[12] TAYEL S A, EI NABRAWI M A, AMIN M M, et al. Sumatriptan succinate sublingual fast dissolving thin films: formulation and in vitro/in vivo evaluation [J]. Pharm Dev Technol, 2016, 21(3):328-337.
[13] LONDHE V Y, UMALKAR K B. Formulation development and evaluation of fast dissolving films of telmisartan [J]. Indian J Pharm Sci, 2012, 74(2): 122-126.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
全军后勤科研重点项目资助(BKJ16J011);全军重大科研计划资助(BKJ16J025)
{{custom_fund}}
PDF(2243 KB)
